Kyowa Hakko Kirin

Summary

Kyowa Kirin Co., Ltd.
TypePublic (K.K)
TYO: 4151
FWB: KY4
Nikkei 225 Component
Industry
FoundedJuly 1, 1949
HeadquartersOhtemachi Building, 1-6-1, Ōtemachi, Chiyoda-ku, Tokyo 100-8185, Japan
Key people
Nobuo Hanai, (CEO and President)
Products
Revenue$ 3.548 billion USD (FY 2013) Increase (¥ 340.61 billion JPY) (FY 2013)
$ 31.32 million USD (FY 2013) Increase (¥ 30.07 billion JPY) (FY 2013)
Number of employees
7,532 (consolidated) (as of December 31, 2017)
ParentKirin Holdings Company, Limited
Subsidiaries47 (33 in Japan and 14 overseas countries)
WebsiteOfficial website
Footnotes / references
[1][2][3]

Kyowa Kirin Co., Ltd. (協和キリン株式会社, Kyōwa Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.[4][5]

History

On July 1, 1949 the forerunner of the present company, Kyowa Hakko Kogyo Co., Ltd. is established. Following the merger with Kirin Pharma Co., Ltd., on October 1, 2008 the company changed its name to its present.

On July 11, 2014, the KHK subsidiary, ProStrakan Group (based in Scotland), acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million [6]

In 2019, the entity was renamed "Kyowa Kirin Co., Ltd.", replacing its prior name of Kyowa Hakko Kirin Co., Ltd.

Business segments and products

  • Pharmaceuticals business

The company developed a method to make afucosylated monoclonal antibodies using a CHO cell line in which FUT8 has been knocked out; the company calls this its "Potelligent" platform. The company gained marketing approval in Japan in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform.[7]

References

  1. ^ "Kyowa Hakko Kirin Company Overview". Kyowa Hakko Kirin. Retrieved March 14, 2014.
  2. ^ "Kyowa Hakko Kirin Corporate Profile" (PDF). Kyowa Hakko Kirin. Retrieved March 14, 2014.
  3. ^ "Kyowa Hakko Kirin Annual Report 2012". Kyowa Hakko Kirin. Retrieved March 14, 2014.
  4. ^ "Components:Nikkei Stock Average". Nikkei Inc. Retrieved January 20, 2015.
  5. ^ "Top 50 Pharma Companies by 2012 Revenue". Wildwood Ventures Ltd. Retrieved March 14, 2014.
  6. ^ "ProStrakan Acquires Archimedes Pharma for $394M". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. July 11, 2014. Retrieved January 20, 2015.
  7. ^ Yu, X; Marshall, MJE; Cragg, MS; Crispin, M (June 2017). "Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering" (PDF). BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 31 (3): 151–166. doi:10.1007/s40259-017-0223-8. PMID 28466278. S2CID 3722081.
  8. ^ "FY 2013 Consolidated Financial Summary". Kyowa Hakko Kirin. Retrieved March 14, 2014.

External links

  • Official website